Phase II Study of Paclitaxel and Carboplatin for Malignant Melanoma

Article Properties
Cite
Hodi, F. Stephen, et al. “Phase II Study of Paclitaxel and Carboplatin for Malignant Melanoma”. American Journal of Clinical Oncology, vol. 25, no. 3, 2002, pp. 283-6, https://doi.org/10.1097/00000421-200206000-00016.
Hodi, F. S., Soiffer, R. J., Clark, J., Finkelstein, D. M., & Haluska, F. G. (2002). Phase II Study of Paclitaxel and Carboplatin for Malignant Melanoma. American Journal of Clinical Oncology, 25(3), 283-286. https://doi.org/10.1097/00000421-200206000-00016
Hodi FS, Soiffer RJ, Clark J, Finkelstein DM, Haluska FG. Phase II Study of Paclitaxel and Carboplatin for Malignant Melanoma. American Journal of Clinical Oncology. 2002;25(3):283-6.
Journal Categories
Medicine
Internal medicine
Neoplasms
Tumors
Oncology
Including cancer and carcinogens
Medicine
Medicine (General)
You May Also Like
Refrences
Title Journal Journal Categories Citations Publication Date
Cancer statistics, 2000 CA: A Cancer Journal for Clinicians
  • Medicine: Medicine (General)
  • Medicine: Internal medicine: Neoplasms. Tumors. Oncology. Including cancer and carcinogens
 2,681 2000
The combination of paclitaxel with cisplatin exhibits antagonism in vitro against human melanoma Anti-Cancer Drugs
  • Medicine: Internal medicine: Neoplasms. Tumors. Oncology. Including cancer and carcinogens
  • Medicine: Therapeutics. Pharmacology
  • Medicine: Public aspects of medicine: Toxicology. Poisons
  • Medicine: Internal medicine: Neoplasms. Tumors. Oncology. Including cancer and carcinogens
  • Medicine: Public aspects of medicine: Toxicology. Poisons
 7 1996
10.1200/JCO.1995.13.3.796 1995
10.1200/JCO.1995.13.3.796 1995
10.1200/JCO.1995.13.8.1840 1995
Refrences Analysis
Category Category Repetition
Medicine: Internal medicine: Neoplasms. Tumors. Oncology. Including cancer and carcinogens8
Medicine: Medicine (General)4
Medicine: Public aspects of medicine: Toxicology. Poisons2
Medicine: Therapeutics. Pharmacology1
The category Medicine: Internal medicine: Neoplasms. Tumors. Oncology. Including cancer and carcinogens 8 is the most frequently represented among the references in this article. It primarily includes studies from CA: A Cancer Journal for Clinicians and Seminars in Oncology. The chart below illustrates the number of referenced publications per year.
Refrences used by this article by year
Citations
Title Journal Journal Categories Citations Publication Date
Is There a Current Role for Combination Chemotherapy or High-Dose Interleukin 2 in Melanoma?

 The Cancer Journal
  • Medicine: Internal medicine: Neoplasms. Tumors. Oncology. Including cancer and carcinogens
  • Medicine: Internal medicine: Neoplasms. Tumors. Oncology. Including cancer and carcinogens
  • Medicine: Medicine (General)
 2024
Chemotherapy in Cutaneous Melanoma: Is There Still a Role?

 Current Oncology Reports
  • Medicine: Medicine (General)
  • Medicine: Internal medicine: Neoplasms. Tumors. Oncology. Including cancer and carcinogens
 9 2023
Modern approaches to treating cancer with oncolytic viruses

 Microbiology Independent Research Journal (MIR Journal)
  • Science: Microbiology
 1 2022
Современные подходы к лечению рака онколитическими вирусами

 Microbiology Independent Research Journal (MIR Journal)
  • Science: Microbiology
 2022
The MEK 1/2 inhibitor PD98059 exhibits synergistic anti-endometrial cancer activity with paclitaxel in vitro and enhanced tissue distribution in vivo when formulated into PAMAM-coated PLGA-PEG nanoparticles Drug Delivery and Translational Research
  • Medicine: Medicine (General)
  • Medicine: Therapeutics. Pharmacology
  • Science: Mathematics: Instruments and machines
  • Medicine: Public aspects of medicine: Toxicology. Poisons
 5 2021
Citations Analysis
Category Category Repetition
Medicine: Medicine (General)51
Medicine: Internal medicine: Neoplasms. Tumors. Oncology. Including cancer and carcinogens46
Medicine: Dermatology10
Medicine: Therapeutics. Pharmacology7
Medicine: Public aspects of medicine: Toxicology. Poisons5
Medicine: Surgery3
Medicine2
Medicine: Internal medicine: Specialties of internal medicine: Immunologic diseases. Allergy2
Science: Biology (General)2
Science: Chemistry: Organic chemistry: Biochemistry2
Medicine: Internal medicine2
Medicine: Internal medicine: Specialties of internal medicine: Diseases of the blood and blood-forming organs2
Medicine: Internal medicine: Specialties of internal medicine: Diseases of the circulatory (Cardiovascular) system2
Science: Microbiology2
Science1
Science: Science (General)1
Technology: Chemical technology: Biotechnology1
Science: Chemistry: General. Including alchemy1
Science: Mathematics: Instruments and machines1
Science: Biology (General): Cytology1
Science: Biology (General): Genetics1
The category Medicine: Medicine (General) 51 is the most commonly referenced area in studies that cite this article. The first research to cite this article was titled BRAF as a potential therapeutic target in melanoma and other malignancies and was published in 2003. The most recent citation comes from a 2024 study titled Is There a Current Role for Combination Chemotherapy or High-Dose Interleukin 2 in Melanoma?. This article reached its peak citation in 2009, with 8 citations. It has been cited in 37 different journals, 13% of which are open access. Among related journals, the Melanoma Research cited this research the most, with 7 citations. The chart below illustrates the annual citation trends for this article.
Citations used this article by year